T
he subject of the compatibility between calcium and phosphates was revisited in an April 1994 FDA safety alert, 1,2 6-16 years after the four seminal research articles appeared in 1978, 3 1980, 4 1982, 5 and 1988. 6 In the 1980s there were two case reports of nonfatal adverse events involving calcium phosphate precipitation in total parenteral nutrient (TPN) admixtures. 7, 8 A review of the main determinants of parenteral drug and admixture compatibility and stability also appeared during that decade. 9 Soon after the April 1994 safety alert, several publications on calcium phosphate precipitation in TPN formulations appeared. [10] [11] [12] [13] [14] [15] [16] [17] [18] Thus, this article is yet another revisit of calcium and phosphate compatibility with i.v. formulations.
This article discusses the chemistry and practical compatibility or solubility factors relevant to the safe administration of combination therapy with calcium gluconate and potassium or sodium phosphate injections. Patient case reports that led to adverse events and pharmaceutical and clinical factors important to calcium phosphate solubility are also presented.
pH and pK a equilibria relevant to calcium and phosphate compatibility. The keys to understanding the chemical reactions and relative risks for calcium phosphate precipitation are as follows:
• The clinically relevant dissociation equilibria for which the pK a2 of phosphoric acid is 7.2 (i.e., the pH at which the concentrations or, thermodynamically, the ionic activities of HPO 4 2- (2) • T h e H e n d e r s o n -H a s s e l b a c h equations 9, 19 : pH = pK a + log ( • The compatibility curves for calcium gluconate versus phosphate concentrations in clinical mixtures. 4, 5, 17, 18 • The influence of other drugs and nutrients. [4] [5] [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] [17] [18] The application of knowledge about calcium and phosphate compatibility in i.v. therapy has been facilitated by four hallmark articles, [3] [4] [5] [6] several editions of the Handbook on Injectable Drugs 17 since 1983, and Trissel's Calcium and Phosphate Compatibility in Parenteral Nutrition. 18 Despite the availability of these literature sources, calcium and phosphate compatibility continues to be a clinical enigma.
Physicochemical factors. Calcium and phosphate solubility chemistry.
The aqueous chemistry and solubility of the two phosphate anions and their calcium salts that are important to the safety of i.v. therapy are summarized in Table 1 . The main facts are as follows: The lower the solution pH is below 7.2, which is the critical pK a2 of phosphoric acid in practice, the greater is the majority percentage of the desired H 2 PO 4 -anion (dihydrogen or monobasic phosphate 19, 20 Note that, typical of most divalent cation-divalent anion salts, CaHPO 4 is minimally dissociated into its constituent ions. Consequently, most of the Ca 2+ and HPO 4 2-ions cannot be solvated by dipolar water molecules via iondipole intermolecular forces, resulting in 0.3-mg/mL solubility in water. Ion-dipole forces generally result in greater solubility in water than do other types of solute-water intermolecular forces. 19, 20 The contrasting high solubility of the divalent cationdivalent anion, magnesium sulfate, at more than 500 mg/mL, results from dipole-dipole forces between water and the mostly nondissociated MgSO 4 ion pairs, which are dipoles. The efficient water solubility of some nonionic organic compounds (e.g., sugars) results from accepting and donating multiple intermolecular hydrogen bonds with water (i.e., one hydrogen bond for at least every four carbon atoms). 20 The percentages of H 2 PO 4 -and HPO 4 2-decrease and increase, respectively, by 1.6% to 5.7% for each 0.1 pH unit increase over the pH range of 6.0-7.6.
14 Because 1 meq of HPO 4 2-corresponds to 2 meq of H 2 PO 4 -, phosphate concentration should be expressed in millimoles per liter, not in milliequivalents per liter. In the article by Schuetz and King, 3 phosphates were reported in milliequivalents per liter but without specific concentrations of H 2 PO 4 -and HPO 4 2-. The appendix shows the calculation for milliequivalents of potassium and for millimoles of phosphates per milliliter in commercial Potassium Phosphates Injection, USP, and for milliequivalents of calcium per milliliter in commercial 10% Calcium Gluconate Injection, USP.
Before the transition to the Pharm.D. degree began achieving national momentum in the 1970s, most U.S. pharmacy schools required courses in qualitative and quantitative chemical analysis and inorganic pharmaceutical chemistry. Those courses were particularly pertinent to the solubility of calcium salts, as illustrated by the following excerpt from a monograph on CaHPO 4 in a standard pharmacy textbook from 1967: "Because this salt is almost insoluble in water, its chemical reactions are few and relatively unimportant. It is soluble in diluted hydrochloric acid." 19 That CaHPO 4 is more soluble at increasingly acidic pH represents the leftward shift in equation 2, and the "unimportance" of CaHPO 4 reactions stated in the 1967 source ended in 1968 with the report that launched TPN, 21 which made reactions between calcium and phosphates in i.v. formulations a matter of life and death.
Calcium and phosphate solubility for i.v. therapy. It is unlikely that any patient-specific i.v. admixture containing calcium and phosphates will exactly duplicate the compatibility results of published studies. Three common variables are (1) practitioner and device volume-measurement accuracy and precision, (2) content and pH ranges from The United States Pharmacopeia and The National Formulary (USP) for calcium gluconate injection (i.e., 95-105% of labeled content and pH 6.0-8.2) and for potassium and sodium phosphate injections (i.e., 95-105% of labeled content), 22 and (3) other drugs and nutrients that may be included in i.v. admixtures (i.e., the variable composition of TPN formulations, which are often patient specific). Even small differences in the USP-allowed percent content ranges of calcium gluconate and potassium or sodium phosphate injections may contribute to the precipitation or nonprecipitation of CaHPO 4 in clinical practice.
The main factors that are important to ensuring total solubility or compatibility of calcium and phosphates in TPN and other i.v. therapy are as follows [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] :
• The mixture should be agitated to achieve homogeneity after each ingredient is added.
• Potassium or sodium phosphate injection should be added early, and calcium gluconate injection should be added last or nearly last to the most dilute phosphate concentration possible. 1, 2, 17, 18 • A 0.2-mm air-eliminating sterile inline filter should be used for nonfat-emulsion-containing i.v. admixtures, and a 1.2-mm filter should be used for fat-emulsion-containing i.v. admixtures. [1] [2] [3] 10, 13, 14, 17, 18 ).
• Calcium chloride injection should never be the calcium source in i. 14 In another study of a simulated TPN admixture, an increase in CaHPO 4 particles larger than 5 mm was measured over 48 hours by using light obscuration, and the precipitates were confirmed as such by petrography and infrared spectroscopy. 23 Demonstration samples of calcium gluconate and potassium phosphate injections. Table 2 illustrates the beneficial effects of the acidic pH of dextrose injection and of calcium sequestration by amino acids on the compatibility of i.v. calcium and phosphates. The approximate calcium and phosphate concentrations of 28 meq/L and 24 mmol/L, respectively, were chosen to intersect well above recommended compatibility curves (Figure 1 ), so that visible precipitation would occur quickly and convincingly in samples with little or no content of dextrose and amino acids. 18 After thorough mixing, the ingredients were added in this order: potassium phosphates, 50% dextrose injection, sterile water for injection (nonbacteriostatic), amino acids, and calcium gluconate. The sample tubes were stored at 22-24 °C and each day were exposed to ceiling fluorescent illumination for 10 hours and to darkness for 12 hours.
The typical results for the samples listed in Table 2 are presented in Table 3 . Adding a few drops of 1.9% (0.05 M) disodium EDTA to sample A or D illustrates calcium sequestration by amino acids when the precipitated CaHPO 4 dissolves, and adding a few drops of 1 N hydrochloric acid to sample A or D illustrates the leftshifted equilibrium in equation 2, which favors calcium and phosphate compatibility. The change from colorless to pale yellow to yellow-amber in samples F, G, and H over 14 days Composite curve for compatibility of calcium (as gluconate) with phosphates at 20-25 °C and pH 6.3 in 25% dextrose injection and 4-4.25% amino acids injection. 4, 5 The farther concentrations are below the curve, the greater the probability of nonprecipitation is, and the closer to or farther above the curve concentrations are, the greater the probability of precipitation of CaHPO 4 is. illustrates the Maillard, or "browning," reaction ( Figure 2 ). 9, 24 This is initially a covalent condensation of primary amino groups on amino acids, R-NH 2 , with the acyclic aldehyde anomer of dextrose (i.e., R-NH 2 + O=CHC 5 H 11 O 5 → R-N=CC 5 H 11 O 5 + H 2 O). 24 The ratio of the aqueous equilibrium of the acyclic aldehyde to cyclic forms of dextrose at pH 6-7 is approximately 0.0025% to 99.9975%. 25 Because of the small percentage of dextrose in the reactive aldehyde form at any given moment, it takes one day to one or more weeks at 20 to 30 °C for Maillard reaction products in mixtures of dextrose and amino acids to reach visible concentrations. The time lapse until the color of Maillard products becomes apparent decreases as the concentrations of dextrose and amino acids increase and increases as the concentrations decrease (e.g., sample F compared with sample H in Table 3 ).
Calcium (meq/L)
Nearly all pharmacists know the importance of hemoglobin A 1c in diabetes management, but few know that A 1c , discovered in 1967, is a Maillard reaction product. 26 Calcium versus phosphate concentration curve. To construct one calcium phosphate solubility curve for use as a general guideline applicable to TPN (Figure 1 ) and perform three models of linear regression, a ruler was used to visually estimate values for 10 and 9 sets of calcium gluconate and phosphate concentrations from figure 1 by Henry et al. 4 and lower curve of figure 5 by Eggert et al. 5 , respectively. The conditions in references 4 and 5 were amino acids, 4.25% 4 and 4% 5 ; dextrose, 25% 4,5 ; pH 6.3; and 20-25 °C. 4, 5 Lower amino acid and dextrose concentrations, which are consistent with low-osmolality and low-osmolarity parenteral nutrient formulations for peripheral vein administration, would move the curve downward and vice versa for higher concentrations of amino acids and dextrose.
The data used to construct the curves in references 4 and 5 were based on visual compatibility and not on particle-size analysis capable of discerning subvisible particulate matter. This is an important point recognizing that unaided visual identification of sparse precipitation is limited to approximately 50-mm individual particles; yet, subvisible precipitates ranging from 5 to 50 mm may occlude the microvasculature, such as in the pulmonary system. 8, 12 The curve in Figure 1 represents a general guideline as one factor for judging compatibility, but it is not possible to predict the precise changes in such a curve for other, unevaluated, concentrations of dextrose and amino acids. The compatibility curves for calcium versus phosphates typified by references 4 and 5 are generally elbow shaped, with a slope slightly left of vertical as calcium declines from 50 to 2 meq/L and phosphates increase from 5 to 8 mmol/L and a slope slightly below horizontal as calcium declines from 14 to 5 meq/L and phosphates increase from 8 to 23 mmol/L. For all such curves, concentration pairs beneath the curves were judged to reflect visual compatibility. 4, 5, 18 To determine the best-fit curve according to the correlation coefficient between the Figure 1 variables of calcium and phosphate concentrations, variations in the mathematical function of the concentrations were applied. The regression of the natural logarithm of calcium concentration versus the natural logarithm of phosphate concentration yielded better correlation (r = -0.99) than the regression of the natural logarithm of calcium concentration versus phosphate concentration and the regression of calcium concentration versus phosphate concentration. Products of calcium concentration (in milliequivalents per liter) with phos- Ingredients are in-date, USP-compliant commercial injections. c Volumes of 0.1 mL and less were measured with a 40-mL (0.04-mL) to 200-mL (0.2-mL) digital pipette; volumes greater than 0.1-2.0 mL were measured with a 100-mL (0.1-mL) to 1000-mL (1-mL) digital pipette; and volumes greater than 2.0 mL were measured in a glass class B10-mL graduated cylinder scaled in 0.2-mL increments. (Figure 3) .
Report by Robinson and Wright. 7 A right subclavian catheter became occluded after 64 days of continuous TPN therapy. The TPN admixture consisted of 500 mL of 8.5% amino acids injection and 500 mL of 50% dextrose injection in a 1000-mL formula that also contained calcium gluconate 10 meq/L and phosphate 80 mmol/L (evenly divided between the sodium and potassium salts). This phosphate concentration greatly exceeds the right-hand limit of 25 mmol/L on the phosphate axis in Figure 3 . The patient survived, probably because a 0.22-mm inline filter was used.
Report by Knowles et al. 8 A patient who had been receiving home TPN therapy for five years developed diffuse granulomatous interstitial pneumonitis due to exposure to precipitated CaHPO 4 . The TPN formulation contained 4.25% amino acids injection and 5% dextrose injection; this is a low-osmolality and lowosmolarity formulation that would be expected to be more susceptible to calcium and phosphate precipitation than, for example, the dextrose concentrations described by Henry et al., 4 Eggert et al., 5 and Fausel et al. 14 Report by Hill et al. 12 This report, which prompted the FDA safety alert, 1,2 involved four patients who had been receiving a low-osmolality TPN admixture via a peripheral vein during hospitalization at Tripler Army Medical Center in Honolulu and who developed sudden and un- 4, 5, 17, 18 were either misinterpreted or not reviewed, (2) the curve for calcium concentration versus phosphate concentration was interpreted as a downward-slanting straight line, 4, 5, 17, 18 (3) a compatibility chart for amounts of calcium gluconate and potassium phosphate injected was based on a final volume of x mL, but the actual volume compounded was 0.5x mL, resulting in twice the assumed concentrations of calcium and phosphates, and (4) an inline filter was not used. One physician who attempted to rescue the baby stated "Ten to 15 minutes into resuscitation, the lower 1-2 cm of the baby's i.v. fluid bag, as well as the i.v. tubing, showed precipitation." Preventing future harm. All institutions must establish calcium and phosphate mixing guidelines that are supported by peer-reviewed literature and the manufacturers' product information. The compatibility guidelines should be based on actual clinical conditions and be reviewed and approved by the pharmacy and therapeutics committee. Low-osmolality and low-osmolarity formulations, such as PN admixtures administered through a peripheral vein, are notorious for calcium and phosphate incompatibility; thus, they should be avoided when possible. A recent investigation of such compatibility for peripheral-vein PN admixtures (≤3% amino acids and ≤5% dextrose) showed that the upper limit of compatibility was calcium gluconate 5 meq/L and sodium phosphates 15 mmol/L, or approximately half the parenteral equivalent of the recommended daily allowance of these minerals. 23 In the early TPN studies used to construct the curve in Figure 1 , 4,5 a limited range of macronutrient concentrations was employed, and only visual identification of precipitation, which can be highly variable, was performed. Recent studies employing particle detection and size measurement by light obscuration provide objective evidence of subvisible microprecipitation, 23 which can be clinically dangerous.
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Careful interpretation of the calcium and phosphate compatibility literature is necessary before application to clinical practice. For example, Wong et al. 27 recently suggested that calcium and phosphate concentrations in TPN admixtures for neonates could be doubled to meet fetal accretion rates by using a formulation containing only monobasic potassium phosphate, KH 2 PO 4 . This claim was based on the correct premise that the divalent phosphate anion, HPO 4 2- , is the culprit in calcium phosphate precipitation in TPN formulations. However, it did not emphasize that increasing pH (e.g., pH in TPN formulations that is much higher than pH in the KH 2 PO 4 injection product) will cause the monobasic anion, H 2 PO 4 -, to convert to the dibasic anion, HPO 4 2-, as depicted in equation 1. In the study by Wong et al., samples were evaluated on three occasions between 0 and 27 hours after admixture preparation. Only 1 of 45 sample measurements exceeded pH 6 (i.e., 6.06) whereas most of the TPN admixtures studied by Henry et al., 4 Eggert et al., 5 and Fausel et al.
14 had a pH of 6.3. Wong et al. 27 would have identified CaHPO 4 precipitation in more samples if the pH had been higher.
Conclusion. Understanding the chemical and practical compatibility of calcium gluconate and potassium or sodium phosphate injections is critical to ensuring the safe i.v. administration of these supplements and preventing patient harm. 
Compatibility and Stability

Calcium and Phosphate
The most important issue to consider in compounding PN solutions is the possibility of forming a calcium-phosphate precipitate, which could occlude microvasculature and be potentially fatal (6) . The risk of developing calcium-phosphate precipitation increases The challenge of keeping TNAs stable resides primarily with the final pH of the formula. Because lipid emulsion carries negative charges on the phospholipid, the integrity of the emulsion state can be disturbed simply by lowering the pH to below 5 or through the presence of cations. As the solution becomes more acidic, more hydrogen ions become available to bind to the negative charges on the phospholipid, compromising the electrostatic repulsion state. In a TNA formula, amino acids not only have a major role in determining the final pH, but they provide a buffering capacity through a unique isoelectric point. Each amino acid molecule has a positive charge on one end and a negative charge on the other, called zwitterions. The presence of both a positive charge and a negative charge in the same molecule of the amino acid strengthens the integrity of a lipid emulsion (20) . The desired pH of a TNA should be in the range of 5.4 to 6.0 (21) . Unlike the TNA solution, the pH for PN (2:1) formulation is largely correlated with the pH of the selected commercial amino acid solutions, which range from 4.5 to 7 (8).
The final concentration of amino acid and dextrose is crucial to keeping the lipid emulsion stable. If the final concentration of amino acid is less than 2% in TNA, the pH is higher than 6.5, and the buffering capacity provided by the amino acid solution is minimal, the risk for lipid destabilization increases. As mentioned earlier, a higher final concentration of dextrose in PN solution increases the viscosity, thereby enhancing lipid stability. Furthermore, the pH for dextrose solution is about 4.0. Therefore, a higher dextrose concentration can compensate for lower amino acid content in a formula that has a low final amino acid concentration but a much higher final dextrose concentration. The recommended final concentration of amino acid is between 20 and 60 g/L at the CCHC Infusion Pharmacy, and the final dextrose concentration is 40 to 250 g/L ( Table 3 ).
The final concentration of the lipid emulsion is also important in TNA stability. If the final concentration is less than 2%, the TNA preparation tends to be unstable due to the dilution effect of the emulsifier. Based on the information provided by Baxter Inc., the CCHC Infusion Pharmacy uses lipid emulsion with a final concentration between 20 and 60 g/L in TNA. As with calcium and phosphate, the order of the compounding sequence can be a factor in TNA stability. Lipid emulsion is added before amino acids and dextrose. The rationale is that the amino acid solution provides a buffering effect for the lipid emulsion, thereby strengthening its electrostatic repulsion state (20) . Because the negative charge on phospholipid is the primary force of stability, cations are potentially capable of neutralizing the negative charge on phospholipids. Divalent cations such as calcium and magnesium are of great concern in TNA preparation. The nutrition support team at the Cleveland Clinic sets the upper limit of calcium plus magnesium to 20 mEq/L or less based on the lipid manufacturer's recommendation. Trivalent compounds such as iron dextran are contraindicated in TNA because they can neutralize the negative charge on phospholipid, but iron dextran is compatible with the PN solution. Table 3 describes acceptable ranges of amino acid, dextrose, lipid, calcium plus magnesium, and calcium-phosphate product in TNAs.
Finally, a storage temperature that is either higher or lower than refrigerator temperature might compromise TNA stability via the breakdown of lipid emulsion (6) . TNA bags should not be placed in freezers because ice crystals might disrupt the phospholipid barriers, and increases in solute concentration during slow freezing could cause precipitation. Therefore, TNA should be stored in the refrigerator at 4.0°C and never frozen. According to USP 797, PN and TNA bags are safe for 7 days from the day they are compounded if they are stored in the refrigerator between 2º and 8°C (6).
Both PN and TNA bags should be removed from the refrigerator and warmed at room temperature for 2 to 3 hours before infusion. When lipid is being infused via a Y-site device, it is only safe for 12 hours at room temperature, according to Centers for Disease Control and Prevention (CDC) guidelines (22) . This incident highlights a pressing safety issue associated with PN orders. In the same publication, ISMP called for a standardized PN order as the top recommendation to avoid a mistake such as that reported. A standardized PN form using grams for amino acid and dextrose, milliliters for lipid, and milliequivalents for all electrolytes would be ideal. The A.S.P.E.N. Safe Practices Guideline made a similar recommendation, with the exception of phosphate salts, which they recommended to be ordered as mmol/day (6).
Compatibility With Medications
In addition, the initial physician order containing each listed ingredient with its appropriate dosage units must synchronize with the pharmacy computer system, the compounder software, and the final PN label. Any PN order must be reviewed by a pharmacist before handing it to a pharmacy technician for computer entry. A pharmacist also should check the accuracy of the entry before sending the order to the IV room for compounding. A second pharmacist in the IV room should double-check the order before sending the PN solution to the floor for infusion. PN solutions must be compounded by experienced and welltrained personnel. Any experienced technician and pharmacist would have recognized that 982 mEq of sodium chloride is absolutely too much for any adult patient, let alone an infant.
Case 2. Converting Micrograms of Zinc
Chloride to Milligrams. A second case published by ISMP on September 6, 2007, described another fatal mistake involving a 1,000-fold overdose of zinc chloride administered to a 26-week-old infant (26) . The initial order asked for zinc chloride 330 µg/100 mL. A pharmacist entering the order into the computer mistakenly chose milligrams (mg) instead of micrograms (µg) as the correct unit. During the compounding, the technician had noticed that 11 vials of zinc chloride solution were requested (correct order should have requested only 0.33 mL) but failed to inform the pharmacist on duty in the IV room. The pharmacist who checked the order in the IV room did not realize that 11 vials of zinc chloride was an unusually large quantity for an order. The floor nurse did not match the initial physician order with the pharmacy label on the zinc chloride bag. The mistake was not identified for 3 hours, and the patient died of cardiac failure due to zinc overdose. This mistake highlights the urgency of setting a standardized ordering form for PN, TNA, and IV fluid orders. Knowing the maximum daily doses for electrolytes or trace element such as zinc chloride in adult and pediatric patients is important for ensuring medication safety.
Another reported mistake in compounding PN is confusion between heparin and insulin, which has resulted in death (27) . The United States Food and Drug Administration (FDA) and ISMP have compiled a list of high-alert medications, which includes insulin, hypertonic sodium chloride, potassium chloride, potassium phosphate, and magnesium sulfate. One approach to avoid confusion in reaching for the wrong bottles when compounding PN solutions is to minimize the number of different strength solutions and separate or color-code different strength stock solutions.
ISMP has compiled a list of error-prone abbreviations, symbols, and dosage designations (28) . Two abbreviations in the list that are most relevant to PN formulating are U and µg. ISMP recommends substituting Unit and mcg for U and µg. For dose designation, they recommend not using trailing zeros for whole number doses (e.g., write 1 mg instead of 1.0 mg). They also recommend using a zero before a decimal point when the dose is less than a whole unit (e.g., 0.5 mg rather than .5 mg).
Automated Compounder
Because a typical PN solution contains at least 10 to 15 ingredients, mixing it manually into a single bag has the potential for many mistakes. An automated compounder can remove much of the human error. Accuracy in the automated compounder relies on bar coding computer technology and a mechanical pump that delivers a specific volume based on the number of revolutions. Using bar coding technology, a PN order is scanned and sent electronically to a compounder, which eliminates possible transcription errors that can occur with manual data entry. At least 20 ports are available in a compounder for handling 20 ingredients. Each ingredient is assigned a specific port with a designated bar code. This step allows for temporal separation of incompatible ingredients, thus reducing the chance of calcium and phosphate precipitating. Each bottle of stock solution already has its own National Drug Code (NDC), and scanning the NDC number and matching the correct port assigned through bar code scanning further ensures the accuracy of source solution identification.
The mechanical pump in an automated compounder can deliver a single ingredient within ±3% of requested volume as long as the needed ingredient volume for compounding is greater than 1 mL. The smallest volume an automated compounder can deliver is 0.2 mL. To ensure the accuracy of a volumetric pump further, an independent weight scale is used to check the final volume pumped. This double-fault protection mechanism is inherently designed in an automated compounder, making the PN compounding process accurate and consistent (4).
Even though an automated compounder is superior to manual compounding, errors still are possible if policies for the entire process are not carried out vigilantly by the pharmacy. The most significant disadvantage of an automated compounder is its cost. The American Society of Health-System Pharmacists (4) published a guideline that included specific objectives related to cost justification:
• Enhanced efficiency and worker safety… and patient safety with PN use.
• Reduction in labor associated with manually compounded PN admixtures.
• Reduction in waste through more efficient use of base solutions and additives.
If a health facility has a high PN patient census, minimizing or eliminating the possibility of medication errors and improving efficiency in overall costs for labor and materials can justify the longterm cost of an automated compounder.
Sterility, USP 797
One of the biggest concerns for patients who receive PN is infection. The most common infection in patients receiving PN is catheter-related bloodstream infection; rarely is infection due to PN solution contamination. However, ISMP recently published a report on an outbreak of Serratia marcescens bacteremia in 19 patients who all received PN from a compounding pharmacy in Alabama in March 2011 (29) . Nine of the affected 19 patients died. The Alabama Department of Public Health (ADPH) and the CDC found traces of S marcescens in the compounding room at the pharmacy. The pharmacy has stopped all production and recalled all compounded preparations. This incident highlights the danger of inadvertently introducing pathogens into PN bags during the compounding process.
Absolute sterility must be maintained in IV rooms used for compounding PN. To achieve the sterility goal, the USP issued Specifically, every person who works in the IV room must be properly trained and able to demonstrate good aseptic techniques such as gowning, gloving, and hand washing. Each facility must develop an action plan that includes written procedures to standardize daily tasks such as gowning, gloving, and hand washing. In addition, quality assurance procedures such as sampling protocols, spill cleanup, personnel training, and regular maintenance logs must be well defined and documented.
Each day, before compounding, pharmacy personnel must clean countertops, shelving, vents, anteroom sinks, and storage bin surfaces using 70% isopropyl alcohol. Trash in the IV room must be cleared out twice daily. Sharps containers with needles and syringes and biohazard containers with chemotherapeutic wastes also need to be cleared out twice daily. By the end of the day, floors must be thoroughly cleaned. Every month, IV rooms, anterooms, walls, ceilings, and storage shelving must be cleaned using the procedures for cleaning a surgical suite.
Monitoring sterility for both airborne and surface area contaminants is another important part of USP 797. Using International Organization for Standardization (ISO) as a guide, USP 797 sets different standards for the number of particles per cubic meter allowed in different areas of an IV room. For example, areas where the actual compounding occurs, such as the hood area, is designated as ISO 5 air environment and the allowed particles are no greater than 3,520 particles/ M 3 . Supporting areas could be classified as ISO 7 or 8 air environment, with allowed concentrations of 10,000 particles/M 3 and 100,000 particles/M 3 , respectively. To ensure that air particles circulating in the clean room contain no contaminants from the external environment, USP 797 requires the clean room to be have negative pressure and to have all entering air passed through a high-efficiency particle air (HEPA) filter.
USP 797 recommends the use of contact plates or swabs to take surface samples from all ISO-classified air environments. Two tests are recommended for testing aseptic technique of personnel operating in the IV room: media-fill test and gloved finger test. Both tests are designed to detect any weakness in aseptic knowledge and technique.
Although seemingly tedious, all of these regulations and standards are absolutely necessary for ensuring patient and worker safety. The challenge for the CDC and APDH is to identify which step or procedure was skipped or missed at the previously cited pharmacy that led to S marcescens contamination in PN bags, resulting in nine deaths.
The FDA is the federal agency that is designated to enforce USP 797 in each health care facility. However, the FDA defers such authority to individual states for regulation and inspection. Some state boards of pharmacy adopt USP 797 fully, but other states only adopt USP 797 partially. The interests of public safety would be best served by universal adoption of USP 797.
Summary
Compounding PN solutions is a complex and complicated process that has inherent safety risks and a very low margin for mistakes. The health care team, including physicians, dietitians, pharmacists, and nurses, must work together to deliver optimum care. Each team member must be vigilant about avoiding harms that might occur during PN order writing, PN formula compounding, or PN solution infusion. Physicians, dietitians, and pharmacists should check every PN formula for compatibility, stability, and safety. 
Invited Review
T he production of fluids for intravenous use is optimally performed in an aseptic environment, and the finished product should be free of microbes, spores, endotoxins, chemical contamination, and physical matter. Compounding such a product requires trained personnel, an adequate environment, and effective technique. 1 However, over the years there have been many reports of contaminated intravenous compounds, including contaminated parenteral nutrition (PN). [2] [3] [4] [5] PN is especially at risk of contamination because it is a mixture of multiple additives and is an excellent growth medium for microbes.
The United States Pharmacopeia (USP), a nongovernmental, nonprofit healthcare organization, is charged with developing national standards for drug purity and safety for all prescription and over-the-counter medicines manufactured or sold in the United States. These standards are published in a book, the United States Pharmacopeia: National Formulary (USP-NF), and healthcare practitioners not familiar with its organization need to understand the significance of each chapter number. Book chapters numbered ≤999 are regarded as medication standards that must be followed and are enforceable by the U.S. Food and Drug Administration (FDA). Those book chapters numbered 1000-1999 are considered informational, whereas chapters assigned numbers ≥2000 are related to nutrition supplements. Because of a low compliance with voluntary guidelines, the USP became involved with issuing standards on the pharmaceutical compounding of sterile products. An expert committee of USP drafted Chapter <797>, the first official monograph enforceable by regulatory agencies concerning the procedures and requirements for pharmacyprepared sterile products, and it became the official minimum standard in January 2004. Much of the same information was previously published as recommendations in the nonenforceable Chapter <1206>, which focused on dispensing for home care and guidelines related to sterile product preparation published by the American Society of Health-System Pharmacists (ASHP). 6 Although Chapter <797> discusses standards applying to all sterile dosage forms that are compounded, only information pertinent to PN and its implications are reviewed here.
Preparation of PN falls under the category of a compounded sterile preparation (CSP) by the definition of USP Chapter <797>. 1 The revised version of USP Chapter <797>, Pharmaceutical Compounding: Sterile Preparation, was released in December 2007 and became official on June 1, 2008. The chapter describes new safety standards for facilities that compound sterile products in an attempt to improve production practices and reduce the risk of contamination. All compounding areas have defined levels of cleanliness and limits of particulate matter, which are defined by International Standards (ISO) Classifications. Table 1 provides these classifications. USP Chapter <797>
Compounding parenteral nutrition, either manually or with an automated compounding device, requires aseptic conditions and trained personnel. The revised version of United States Pharmacopeia Chapter <797> is a comprehensive document that describes standards and procedures to minimize the risk of contamination of compounded parenteral products. The chapter includes evidence-based instructions for pharmacy design, washing, garbing, cleaning, quality assurance, and personnel training and evaluation designed to improve compounding practices in all pharmacies that compound parenteral products. Because parenteral nutrition is a compounded product mixed from multiple additives, it is important to maintain these standards, especially when using an automated compounding device. is an official document of the USP-NF and is therefore enforceable by the FDA. 6 Because the FDA allows individual states to regulate the practice of pharmacy, it is usually up to the state board of pharmacy to adopt the standards and inspect pharmacies for compliance. 7 However, the FDA does have the power to inspect pharmacies and enforce the standards in the interest of public health. Medication recalls and additional legal sanctions can occur upon failure to comply with USP standards.
Compliance with the USP Chapter <797> standards may require multiple changes in the way that pharmacy personnel operate while preparing CSPs. The standards describe in detail the environments for preparation of sterile products, cleaning of equipment and surfaces, personnel training, washing and garbing procedures, and quality assurance checks. This article summarizes the new standards and also outlines the specific sections which pertain to compounding PN.
Pharmacy Design
USP Chapter <797> outlines a 3-tiered approach for assigning the potential risk of contamination associated with compounding of CSPs ( Table 2) . PN is classified as a "medium-risk-level" CSP when it is prepared from crystalline amino acids and commercially available monohydrated dextrose, injectable lipid emulsions, electrolytes, multiple vitamins, trace elements, and sterile water. It carries a higher level of risk because it requires the mixing of multiple small doses of different sterile products into 1 large bag.
1 When PN is compounded using powdered amino acids, it is classified as a "high-level" CSP because its preparation involves the use of nonsterile ingredients and carries the highest risk for contamination by microbial, chemical, or physical matter. As a result, high-risk-level CSPs must undergo some type of sterilization process prior to administration. All risk-level compounds should be prepared in an environment in which particulate matter and microorganisms are minimized, and the air quality must meet certain standards. Pharmacies must be designed specifically to meet these standards, which require an anteroom and a buffer area to separate the general environment from the area of compounding. The lower the number of classification, the cleaner the air must be. The anteroom is an area where personnel can perform washing and garbing procedures prior to entering the compounding area, and it must meet ISO class 8 requirements. After personnel have garbed and washed, they must enter the buffer area. The buffer area must be separated from the anteroom by demarcation or a physical barrier. If the buffer area is physically separated from the anteroom, it must be an area of positive pressure and meet ISO class 7 requirements. A positive-pressure room is defined as a room that has a higher pressure than adjoining rooms so that the air flows out of the room. 1 The buffer area must be kept as clean and as free of particulates as possible, because this is the area where products are gathered directly before compounding takes place. All materials in this area, including furniture, equipment and supplies, must be nonpermeable, nonshedding, cleanable, and resistant to damage by disinfectants. All materials should be cleaned and disinfected before entering the buffer area. Finally, the cleanest area must be the area where compounding occurs, called the direct compounding area (DCA), which must meet ISO class 5 standards. The DCA airflow must be controlled by 1 of the following devices: laminar airflow work benches, biological safety cabinets, compounding aseptic isolators, or compounding aseptic containment isolators. All areas should be constructed so that the space minimizes dust and dirt collection. Counters, shelves, and carts should be constructed of smooth, nonporous, nonshedding materials such as stainless steel or molded plastic that are able to be cleaned and disinfected on a regular basis. Walls and ceilings must be constructed of nonporous materials, such as heavy-gauge polymer or epoxy-coated gypsum board. Other fixtures, such as hanging light fixtures or pipes, should be minimized.
Anterooms are to be free of food, drinks, and materials that have been exposed to patient care areas. In the anteroom, all package compounding supplies, including needles, syringes, tubing sets, and small-and large-volume parenteral products, must be taken out of cartons and wiped with sterile 70% isopropyl alcohol before they are transferred to the buffer area. An apparent demarcation must separate the anteroom and the buffer area, whether it is a line on the floor or a physical separation, such as a door.
Cleaning and Garbing Procedures
To maintain ISO class 5, 7, and 8 standards, personnel must strictly adhere to washing and garbing procedures before entering the areas. First, in the anteroom, before entering the buffer area, personnel should remove all outer garments and any hand, wrist, or ear jewelry. Next, personnel should put on appropriate garb, in the following order: shoe covers, head covers, and face masks. Personnel should wash hands and forearms with soap and water for 30 seconds and dry with lint-free disposal towels or electronic hand dryer. After the hand-cleansing procedure, personnel should put on a nonshedding gown with cuffs at the wrists and closure at the neck. They may enter the buffer area after appropriate garbing and must use waterless alcohol-based surgical hand scrub to clean their hands before donning sterile, powder-free gloves. Gloves should be kept clean throughout the day by wiping or rubbing 70% isopropyl alcohol to all surface areas of the gloves, and this cleansing should take place after the gloves make contact with any nonsterile surface.
After personnel have finished with cleansing and garbing procedures, they should begin cleaning the work area. Personnel should clean and disinfect surfaces in the primary compounding area at the beginning of every shift, before a new batch is started, every 30 minutes during continuous compounding, when there are spills, and when known contamination is present or suspected. Counters and floors must be cleaned daily with nonshedding wipers and mops dedicated to each area. For instance, sponges used to clean the buffer area should stay in the buffer area. Cleaning elements should be disposable if possible. If cleaning elements are not disposable, then they should be cleaned by standard procedures on a regular basis. Walls, ceilings, and shelving must be cleaned monthly. All cleaning should be done by trained personnel with approved cleaning and disinfecting agents.
To maintain ISO standards, it is important to avoid extraneous particles and microbes. All supplies brought into the buffer area must be removed from cardboard cartons in an anteroom before being passed into the buffer area in order to minimize airborne particulates. To decrease microbial contamination, all supplies including needles, syringes, tubing sets, vials, and small-and largevolume parenteral products should be cleaned and disinfected with sterile 70% isopropyl alcohol before being transferred to the buffer area. All equipment that is brought into the buffer area must be cleaned and disinfected, including carts and storage containers.
Personnel Training and Evaluation
To be compliant with USP Chapter <797>, institutions must show that all personnel are trained in garbing procedures, aseptic work practices, and cleansing/disinfection procedures. Institutions must document that personnel complete didactic training, pass written competencies, and undergo skill assessment using observational audit tools and media-fill testing. Annual documentation of successful completion of written and media-fill testing is required for all personnel who perform low-and medium-risk-level compounding, and semiannual documentation is required for personnel who perform high-risk-level compounding. Appendices in USP Chapter <797> provide excellent tools for assessment of procedures by direct observation. 1 To ensure proper hand hygiene, garbing procedures, and cleaning and disinfection procedures, a pharmacy supervisor directly observes the compounding personnel while they perform the procedure. To pass the aseptic technique competency, compounding personnel must pass both a direct observation test and a media-fill test. Mediafill testing assesses the quality of aseptic technique and provides objective evidence of production of a sterile product. To pass this competency, personnel use commercially available sterile fluid culture media, such as soybeancasein digest medium, to simulate a drug product for compounding. If the medium is not transferred from 1 container to another aseptically, bacteria will grow and will be visibly turbid. For successful completion, the compound must be incubated and must not be turbid for 14 days after manipulation. 1 Compounding personnel who fail written or observational assessment, or whose aseptic technique results in contamination, must be reinstructed and retested until they pass all portions of assessment.
Quality Assurance
All of the compounding and associated areas must be tested periodically to prove that the areas meet particulate and cleanliness standards. Except for pressure differentials, this environmental sampling should occur and be documented as part of the certification of new facilities or equipment as well as for recertification, which should occur every 6 months. Environmental sampling should also occur after any equipment is serviced and after physical changes have been made to the area (eg, new construction, rearrangement). Sampling must occur in response to patient-care-related infections when the sterile product area may be at fault or in response to suspected suboptimal work practices of compounding personnel.
The environment should be sampled for airflow between areas, nonviable particulates, and viable particulates (viable refers to microorganisms). Airflow should be measured between the buffer area and the anteroom, and between the anteroom and the general environment outside the anteroom. Airflow should be monitored and documented at least every work shift. Nonviable and viable particulates are measured less often, as stated previously. Nonviable particulates are measured to make sure that the various levels of cleanliness are being maintained by the devices that maintain ISO class 5 environments. Viable particulates are measured in select sampling sites to ensure the lowest levels of antimicrobial invasion into the compounding area. Sampling sites should include areas of the greatest risk of contamination, such as work areas near passageways or counters located in an area of high air turbulence. The chapter outlines in detail the materials needed for testing, including viable air sampling devices, type of agar or growth medium plates, and incubation conditions and time. 1 Environmental sampling should be part of the standard operating procedure of the pharmacy. As such, the procedure for measuring and documenting environmental sampling should include a sampling plan that defines acceptable limits for pressure gradients and nonviable and viable particles. The plan should instruct pharmacy personnel on what steps to take if the samples exceed the acceptable limits.
Quality Assurance for PN Compounding
It has been estimated that 65% of all PN admixtures in the United States are prepared with automated compounding devices (ACDs), a practice that is permissible under USP Chapter <797> standards. 8 Guidelines for ensuring the accuracy and precision of ACDs are addressed in this chapter. Compounding personnel should test the device for accuracy on a daily basis, document the results, and then review the results weekly. Personnel should perform both volumetric and weight testing using sterile water for the fluid test. Other additives may be tested if desired. Additional tests using the hospital laboratory may be used to ensure accurate compounding, such as testing for dextrose or for potassium concentration in the final compounded preparation. Other fundamental elements related to the safe and cost-effective inclusion of this technology into pharmacy operations have been addressed by ASHP guidelines published in 2000. 8 As many as 20 single-source containers are attached to an ACD during PN compounding, all of which are pumped into a single large-volume plastic bag. The order in which individual ingredients are added to the final PN admixture is very important because specific components may be incompatible if added too close together in the sequence (eg, calcium gluconate and sodium/potassium phosphate). Use of the ACD for purposes other than PN compounding should be discouraged because this will likely require reprogramming of configurations and increase the risk for error. Compounder tubing changes must occur at appropriate time intervals in keeping with manufacturer recommendations, or mortality from infected solutions can result. 9 During the course of a work shift, single-source containers may be replaced several times during the compounding process-all of which is performed within an ISO class 5 environment. Strict aseptic practices must be followed by the pharmacist during these changes of additive source containers to reduce the risk of contamination. Minimum performance standards for quality assurance of compounding procedures should also be established. If changes in the accuracy of delivering a single additive (eg, potassium chloride) exceed a predetermined percent error, a plan for implementing corrective actions should be in place. All large-volume PN components (ie, amino acids, dextrose, and lipid emulsions) should be acquired from 1 manufacturer unless published data exist to substantiate the safety, compatibility, and stability of alternative final admixture formulations.
Compounding personnel should inspect the physical appearance of the final PN formulation. 10 Although microprecipitates and incompatibilities cannot be seen by the naked eye, large-particle contaminants or precipitates are the most likely to immediately harm the patient, and they can easily be detected before the product is dispensed. For PN formulations without lipid emulsions, the product should be inspected against a dark background for the presence of particulates, such as fibers from alcohol swabs, cores of additive vials, or insoluble precipitates. Compounding personnel should also look for any signs of crystallization or for haziness of the product. For PN admixtures with lipid emulsions, compounding personnel should examine the bag for any signs of a cracked emulsion, including separation of components into an oil layer or into fat droplets. Finally, access and use of any ACD equipment for PN preparation should only be available to personnel who have been appropriately trained and demonstrated competency in this area. 8 
Final Checks and Tests
Labeling
The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Safe Practice guidelines outline best practices for labeling PN (Figure 1) . 10 This format provides the most straightforward way of displaying ingredients in the formulation, as well as other required elements for intravenous compounds, including route of administration, date and time for administration, beyond-use date, dosing weight, and rate. Compounding personnel should have a standard procedure for verifying the contents of the finished product by comparing the finished labeled PN product to the original order. 1 The best way is to have a double-checking procedure in place. If additives are added manually to the bag, original containers (ie, vials) should be grouped with the final product; if the entire vial is not used, a syringe pulled back to the volume of the product measured should accompany the vial and the final product.
Storage and Use of PN Admixtures
A beyond-use date should appear on the PN label. A beyond-use date is different from an expiration date. Whereas expiration dates are based on rigorous tests for the chemical and stability of manufactured sterile products, beyond-use dates are based on the risk level of the CSP with consideration given to the time and temperature at which the preparation will be stored. According to USP Chapter <797> standards, a beyond-use date for a PN admixture prepared for inpatient administration is 30 hours based on storage at room temperature and a medium-risk-level (see Table 1 ). In the home-care environment, the beyonduse date can be extended to 9 days as long as PN admixtures are stored at 2°-8° C (36°-46° F) until use. The 30-hour time limit still applies once PN infusion is initiated.
Summary
Compounding of PN is not without its risks, but the standards outlined in USP Chapter <797> greatly reduce risks of contamination of microbial or particulate matter. Most pharmacies will need to change their physical design to provide space for an anteroom and buffer area surrounding direct compounding areas. Washing and garbing are important steps in maintaining a clean environment, as is regular cleaning with approved agents. Quality assurance tests, including testing of air; aseptic technique; and personnel compliance with standard operating procedures are important to maintain a clean environment with minimal airborne particulates. Although many of these changes may be difficult and expensive to achieve, they will all lead to safer compounding practices and provide the patient with the best end product. 
